Intellia Therapeutics (NTLA) PT Lowered to $79 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Price: $13.07 +3.73%
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 19
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 19
Join SI Premium – FREE
JPMorgan analyst Brian Cheng lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $79.00 (from $82.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Morgan Stanley Downgrades Sandfire Resources NL (SFR:AU) (SNDFY) to Underweight
- BHP (BHP:LN) (BHP) PT Raised to GBP36.56 at Morgan Stanley
- Independence Group NL (IGO:AU) (IPGDF) PT Lowered to AUD6.40 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
